2026-06-14T02:28:48Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/155032024-09-27T22:25:55Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Sánchez, Antonio J author Puerta, Carmen author Ballester, Sara author González, Paz author Arriaga, Angel author García-Merino, Antonio author 2005-11 Rolipram suppresses experimental autoimmune encephalomyelitis (EAE) and diminishes cell infiltration of the central nervous system (CNS). In Lewis rats with EAE, rolipram reduced matrix metalloproteinase-9 (MMP-9) gene expression in lymph node cells (LNCs) and spinal cord, decreased basal levels of nuclear (p50/p65) NF-kappaB in LNCs from treated rats, and impaired CD3 mediated NF-kappaB translocation. Rolipram reduced the luciferase activity directed by the NF-kappaB binding site of the MMP-9 gene in lymphocytes. It also diminished NF-kappaB activity and the ability of a myelin basic protein (MBP) specific cell line to migrate across artificial basement membranes. IL-2 induced MMP-9 proteolytic activity was only slightly reduced indicating that additional factors contribute to inhibit cell migration mediated by rolipram. J Neuroimmunol. 2005 Nov;168(1-2):13-20. 10.1016/j.jneuroim.2005.03.024 0165-5728 Journal of neuroimmunology 16182379 http://hdl.handle.net/20.500.12105/15503 Experimental autoimmune encephalomyelitis Rolipram Nuclear factor kappa B Matrix metalloproteinase-9 Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis